Data-Led Summit for B2B Leaders
200+ business leaders from the global cannabis industry come together to discuss the future of trade, innovations and policy in Europe's most important emerging market.
In June 2026, Business of Cannabis & Prohibition Partners return to Berlin for a half-day leadership summit full of data and actionable insights.
The European Cannabis Insights Summit will connect, inspire, and inform 200 top cannabis industry leaders from Germany and across Europe. Dive into groundbreaking new and exclusive datasets, learn innovative strategies, and forward-thinking practices that will evolve Germany's dynamic cannabis market and the broader European landscape.
More than 200 global cannabis leaders, innovators, and decision-makers will join us in an intimate conference space in Berlin for an unprecedented day of international trade, networking, and business opportunities. Don't miss this unparalleled opportunity to gain access to crucial information to help inform your decision making process as a cannabis leader in the international market.
Full access to the European Cannabis Insights Summit — all sessions, panels, networking, and data presentations in Berlin, June 10 2026.
Summit entry plus Prohibition Partners' exclusive German market data summary and market sizing pack.
Prohibition Partners × Business of Cannabis
This exclusive post-event report (PDF) and dataset (Excel workbook) covers market sizing, product pricing and wholesale data across key European cannabis markets. A dedicated Patient Patterns chapter follows after the event.
Available exclusively as a bundle with your summit ticket. The essential intelligence tool for cannabis leaders operating in Europe.
PDF report + Excel dataset · Patient Patterns chapter delivered post-event
A confirmed roster of senior operators, analysts, founders and policy leaders shaping the next chapter of cannabis in Europe — with more speakers still to be announced.
Interested in speaking at the European Cannabis Insights Summit?
Apply to SpeakThe implementation of the Cannabis Act (CanG) in Germany in 2024 fundamentally transformed the medical cannabis landscape, shifting the market from a tight system to one that genuinely reflects population demand. This regulatory change led to a significant surge in patient volume, particularly via telemedicine, confirming the considerable latent demand previously suppressed by systemic barriers. Our panel will examine longitudinal data to understand how this increased access has fundamentally changed patient characteristics and behaviours. The discussion will also include how the influx of new patients is impacting the overall prescribing landscape, especially in relation to the convergence of THC content and the standardisation of protocols among prescribers.
The trajectory of cannabis reform in Europe will be shaped by an interplay of policy decisions, pricing dynamics, patient access and investor confidence, and the picture looks different depending on which variables you prioritise. This session takes an evidence-based approach to market forecasting, using adjustable scenario modelling and live discussion to stress-test assumptions about Germany and other key markets. Attendees will leave with a sharper framework for evaluating how near-term developments could translate into medium-term commercial and regulatory outcomes.
Adult-use pilot programmes across Europe are no longer theoretical policy experiments. They are becoming structured data environments designed to answer some of the most important questions in cannabis regulation. This session brings together leading operators and compliance technology providers to explore what these trials are actually measuring, and whether they are delivering the evidence policymakers think they need. Focusing on the role of real-world data, compliance systems and supply chain tracking, the discussion will examine which metrics matter most for regulators, how trial objectives are evolving as programmes mature, and what early results are revealing about consumer behaviour, product demand, pricing dynamics and public health outcomes. Speakers will also explore where misconceptions still exist, what evidence is most likely to influence future policy decisions across Europe, and what investors and operators should be watching over the next 12 to 24 months as pilot programmes move from experimentation to precedent-setting policy tools.
As medical cannabis access expands across Europe, the debate is increasingly shifting from whether patients can access treatment to who those patients actually are. This session uses reimbursement data, prescribing patterns and patient-level demographics to build a clearer picture of the modern cannabis patient, and how different profiles are shaping demand across medical systems. Focusing on Germany as the most data-rich European market, the discussion will explore age, gender, indication clusters, regional variation and treatment pathways, alongside how patients are actually paying for their medicine through statutory reimbursement, private prescriptions and hybrid models. Speakers will examine how reimbursement rules shape patient access in practice, what the data reveals about underserved or overrepresented groups, and how patient profiles differ depending on product type, prescribing channel and insurance coverage. The session will close by asking what a clearer demographic picture means for future market design, clinical guidance and payer strategy.
A functioning cannabis market depends on supply chains that can absorb regulatory pressure, price volatility and shifting demand without breaking down. This session examines the latest data on import and export flows, wholesale pricing and retail dynamics across Europe's key markets, mapping where supply routes are holding and where they are under strain. Speakers will address how structural differences between national markets create both risk and opportunity for operators managing multi-jurisdictional supply, and what that means for long-term commercial planning.
Close out the summit with drinks and conversation alongside speakers, sponsors and fellow delegates in central Berlin. Hosted with our partners at Aurora.
Pick a template, drop in your logo or headshot, and download a ready-to-post graphic for LinkedIn, Instagram, and beyond.
Upload your logo or headshot to begin
PNG with a transparent background works best. Max 10 MB.
Drag the image on the preview to reposition. Drag the bottom-right corner to resize, or use the slider.
The companies investing in Europe's cannabis future will be in the room with you on 10 June.
Frankfurt-based and founded in 2020, Bloomwell Group is one of Europe's leading medical cannabis companies — a digital ecosystem spanning the value chain outside cultivation. It serves more than 100,000 patients, pharmacies, physicians and wholesalers every month and is a European pioneer in telemedicine, digital payment integration and qualified e-prescription solutions for medical cannabis.
"To overcome decades of prejudice that cloud cannabis regulation, we must shift the conversation from fear to facts. The answer to advancing the medical cannabis sector and improving patient access is data-driven, not ideologic."
Operating since 2019, alephSana is a fully licensed pharmaceutical wholesaler and established medical cannabis supplier in Germany. It provides pharmacies with a growing portfolio of high-quality cannabis products from GMP- and GDP-certified producers, and supports licensed international manufacturers seeking trusted access to the German market.
Founded in Berlin in 2018 by Finn Age Hänsel, Sanity Group develops cannabinoid-based pharmaceuticals and consumer goods to improve quality of life through the endocannabinoid system. The group spans Vayamed, avaay Medical and ZOIKS in medical cannabis, Endosane Pharmaceuticals, lifestyle brand vaay, and Grashaus Projects — a Swiss recreational pilot — and operates a logistics and production facility for cannabis pharmaceuticals near Frankfurt am Main.
The digital twin of your cannabis operations — software that streamlines production processes and helps operators comply with international standards, from cultivation through to distribution.
Closing the summit with drinks and conversation in central Berlin — alongside speakers, sponsors and fellow delegates.
auroramedical.com
A global communications and events agency with offices in the UK and US — specialising in emerging markets, health & wellness, and B2B/B2C PR.
americanapr.comWant to join them?
Become a SponsorThe combined network of Business of Cannabis and Prohibition Partners is the largest B2B audience in the global cannabis industry. Don't just take our word for it — read the numbers for yourself.
Previous Sponsors & Exhibitors
ECIS Summit 2026 takes place at Palisa.de — a contemporary event space in eastern Berlin, a short walk from Ostbahnhof and the Spree.
Palisa.de is located on the third floor (the top floor). If taking the elevator, this floor is marked with “D" which stands for the German word Dachgeschoss (top floor).
The Annual Leadership Conference for Key Executives Building the Cannabis Industry Globally
Providing crucial data, insights and networking opportunities to drive growth across the industry — from Germany's dynamic domestic market to the broader European and international landscape.
Berlin · June 10, 2026
Exclusive data, unparalleled networking, and the intelligence to drive your decisions in the European cannabis market.
